• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.

作者信息

Goldman Stan, Barth Matthew, Shiramizu Bruce, Shi Qiuhu, Hochberg Jessica, Klejmont Liana, Harrison Lauren, Basso Jackie, Chu Yaya, Islam Humayun, Gerard Perry, Agsalda-Garcia Melissa, Shieh Tiffany, Oesterheld Javier, Heym Kenneth, Kirov Ivan, Drachtman Richard, Harker-Murray Paul, Perkins Sherrie, Miles Rodney R, Cairo Mitchell

机构信息

Department of Pediatric Hematology/Oncology, Medical City Children's Hospital, Dallas, TX, USA.

Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY, USA.

出版信息

Leukemia. 2021 Oct;35(10):2994-2997. doi: 10.1038/s41375-021-01256-8. Epub 2021 May 3.

DOI:10.1038/s41375-021-01256-8
PMID:33941850
Abstract
摘要

相似文献

1
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.在低危成熟B细胞淋巴瘤儿童和青少年中用剂量密集型利妥昔单抗替代蒽环类药物强度进行剂量替换。
Leukemia. 2021 Oct;35(10):2994-2997. doi: 10.1038/s41375-021-01256-8. Epub 2021 May 3.
2
Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.蒽环类药物减量序贯联合化疗用于预后良好的年轻侵袭性B细胞非霍奇金淋巴瘤患者
J Cancer Res Clin Oncol. 2009 Mar;135(3):459-66. doi: 10.1007/s00432-008-0467-2. Epub 2008 Aug 29.
3
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.利妥昔单抗、苯达莫司汀和来那度胺治疗不适合蒽环类药物治疗或强化挽救化疗的侵袭性 B 细胞淋巴瘤患者 - SAKK 38/08。
Br J Haematol. 2016 Jul;174(2):255-63. doi: 10.1111/bjh.14049. Epub 2016 Mar 28.
4
Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.苯达莫司汀、利妥昔单抗和匹杉琼联合治疗复发/难治性B细胞非霍奇金淋巴瘤的I期研究
Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):679-686. doi: 10.1016/j.clml.2018.07.285. Epub 2018 Jul 29.
5
[Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].19例复发性儿童B细胞淋巴瘤的临床病理特征及治疗结果
Zhonghua Er Ke Za Zhi. 2017 Oct 2;55(10):748-753. doi: 10.3760/cma.j.issn.0578-1310.2017.10.007.
6
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.一项关于标准剂量与高剂量利妥昔单抗联合BEAM方案用于复发侵袭性B细胞非霍奇金淋巴瘤自体干细胞移植的随机II期研究：长期结果
Br J Haematol. 2017 Aug;178(4):561-570. doi: 10.1111/bjh.14731. Epub 2017 May 9.
7
Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives.儿童和青少年成熟B细胞淋巴瘤及白血病——标准化疗方案综述与展望
Pediatr Hematol Oncol. 2013 Sep;30(6):465-83. doi: 10.3109/08880018.2013.783891. Epub 2013 Apr 9.
8
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.弥漫性大B细胞淋巴瘤患者蒽环类药物剂量优化：一项多中心、3期、随机对照试验。
Lancet Haematol. 2019 Jun;6(6):e328-e337. doi: 10.1016/S2352-3026(19)30051-1.
9
[Treatment of primary mediastinal large B-cell lymphomas].[原发性纵隔大B细胞淋巴瘤的治疗]
Orv Hetil. 2004 Dec 12;145(50):2531-7.
10
Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.利妥昔单抗联合疗法治疗复发/难治性儿童B细胞非霍奇金淋巴瘤：来自日本儿童白血病/淋巴瘤研究组的报告
Pediatr Blood Cancer. 2016 Oct;63(10):1794-9. doi: 10.1002/pbc.26105. Epub 2016 Jun 17.

引用本文的文献

1
Rituximab for children with EBV-positive Burkitt lymphoma in East Africa.利妥昔单抗用于东非患有EBV阳性伯基特淋巴瘤的儿童。
Blood Adv. 2025 May 27;9(10):2393-2401. doi: 10.1182/bloodadvances.2024015234.
2
Use of rituximab in mature, high-grade and advanced-stage pediatric B-lineage non-Hodgkin lymphomas: a systematic review, meta-analysis and the Brazilian reality.利妥昔单抗在成熟、高级别和晚期儿童B细胞系非霍奇金淋巴瘤中的应用：一项系统评价、荟萃分析及巴西实际情况
Front Pediatr. 2025 Jan 20;13:1532274. doi: 10.3389/fped.2025.1532274. eCollection 2025.
3
binding domain mutations are bad news in Burkitt lymphoma.
结合结构域突变在伯基特淋巴瘤中是个坏消息。
Haematologica. 2024 Sep 1;109(9):2775-2777. doi: 10.3324/haematol.2024.285213.
4
Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children's Cancer Group Multicentre Trial, JPLSG B-NHL-20).利妥昔单抗联合不含蒽环类药物的化疗方案治疗新诊断的非高危侵袭性成熟 B 细胞淋巴瘤的儿科和青少年患者：单臂、开放标签、多中心、Ⅱ期研究方案（日本儿童癌症研究组多中心试验，JPLSG B-NHL-20）。
BMJ Open. 2024 Mar 19;14(3):e080762. doi: 10.1136/bmjopen-2023-080762.
5
Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.儿童、青少年及青年人群侵袭性非霍奇金淋巴瘤的管理：成人视角与儿童视角对比
Cancers (Basel). 2022 Jun 13;14(12):2912. doi: 10.3390/cancers14122912.